Sagent Pharmaceuticals – FDA 483, Dec 18, 2019
Sagent Pharmaceuticals Inc. in Schaumburg, IL, received a Form 483 with seven observations highlighting significant deficiencies in its quality control unit's oversight of contract manufacturers and adherence to procedures. The firm failed to ensure proper approval and rejection of drug products, investigate temperature excursions, and submit timely field alert reports for contamination and out-of-specification products. These issues, coupled with inadequate staffing and documentation errors, indicate a systemic breakdown in quality assurance and regulatory compliance.
ID · cdb3159c-250b-4e80-b62d-bf743d51a811
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.